AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25891551 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measures of atrophy (BPV, GMV, NAWMV)
Number of subjects: 43
Study 25891551 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in SIENA (1%)
Number of subjects: 43
Study 25891551 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in brain volume SIENA (1%)
Number of subjects: 43
Study 22873943 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexTouch® (FT)
Number of subjects: 120
Study 20514495 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 24
Study 20514495 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 24
Study 20514495 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 24
Study 20514495 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 24
Study 18727478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 216
Study 18727478 — intervention group
Group type: COMPARATOR
Intervention: Drugs only (Control)
Number of subjects: 216
Study 15908299 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenge tests with NSAIDs
Number of subjects: 260
Study 12766095 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly remunerated routine chiropodist care (n = 47)
Number of subjects: 91
Study 12766095 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 44)
Number of subjects: 91
Study 12766095 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropodist care per protocol (n = 47)
Number of subjects: 91
Study 10819735 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching interventions during home care
Number of subjects: 148
Study 8844033 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam loading dose therapy (40 to 210 mg, mean 86.9 ± 47.2 mg)
Number of subjects: 96
Study 8844033 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy (diazepam and other psychotropic drugs in divided doses)
Number of subjects: 96
Study 1906074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based feeding
Number of subjects: 44
Study 1906074 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-based feeding
Number of subjects: 44
Study 1906074 — intervention group
Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 44
Study 6345501 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (up to 120 mg per day)
Number of subjects: 5
Study 6345501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31801742 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Number of subjects: 422
Study 29272029 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call from a nurse using a scripted questionnaire
Number of subjects: 2000
Study 29272029 — intervention group
Group type: COMPARATOR
Intervention: Satisfaction survey only (Control)
Number of subjects: 2000
Study 26610165 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo cream with suggestion of reduced skin reaction
Number of subjects: 48
Study 26610165 — intervention group
Group type: COMPARATOR
Intervention: Control session (no treatment)
Number of subjects: 48
Study 25325498 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil (150 mg)
Number of subjects: 20
Study 22811410 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 70 mg/m² Days 1 and 29 and 5-fluorouracil 700 mg/m² Days 1-5 and 29-33 with radiotherapy 60 Gy/30 fr/7 weeks (arm A)
Number of subjects: 91
Study 22811410 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 7 mg/m² Days 1-5, 8-12, 29-33 and 36-40 and 5-fluorouracil 250 mg/m² Days 1-14 and 29-42 with the same radiotherapy (arm B)
Number of subjects: 91
Study 22811410 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 91
Study 20099948 — intervention group
Group type: EXPERIMENTAL
Intervention: Precaution Adoption Model (PAM)
Number of subjects: 133
Study 20099948 — intervention group
Group type: COMPARATOR
Intervention: Behavioral Action Model (BAM)
Number of subjects: 133
Study 19069889 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microg intravaginally, 2 times at 6 h intervals)
Number of subjects: 110
Study 19069889 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (6 mu min(‐1) infusion)
Number of subjects: 110
Study 16245968 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.2 mg/mL for 5 min)
Number of subjects: 14
Study 16245968 — intervention group
Group type: COMPARATOR
Intervention: Control (no mitomycin C)
Number of subjects: 14
Study 12081834 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (30 mg/d)
Number of subjects: 21
Study 12081834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 12081834 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 21
Study 9861326 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg daily)
Number of subjects: 8
Study 9861326 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 8
Study 8583134 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units of interferon alfa‐2b thrice weekly for 6 months
Number of subjects: 230
Study 8583134 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 million units of interferon alfa‐2b thrice weekly for 6 months
Number of subjects: 230
Study 8583134 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units of interferon alfa‐2b thrice weekly for 2 years
Number of subjects: 230
Study 8583134 — intervention group
Group type: COMPARATOR
Intervention: 6 months treatment
Number of subjects: 230
Study 8583134 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years treatment
Number of subjects: 230
Study 8583134 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of cirrhosis
Number of subjects: 230
Study 8583134 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of cirrhosis
Number of subjects: 230
Study 8583134 — intervention group
Group type: EXPERIMENTAL
Intervention: Injecting drug use
Number of subjects: 230
Study 8583134 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 230
Study 8583134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sporadic cases
Number of subjects: 230
Study 8583134 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years treatment vs 6 months treatment
Number of subjects: 230
Study 2164415 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 20
Study 2164415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7267673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin 500 mg twice daily
Number of subjects: 752
Study 7267673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin 1 g twice daily
Number of subjects: 752
Study 7267673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin (both dosages)
Number of subjects: 752
Study 30513252 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP‐IPV‐HB‐PRPT primary and booster vaccination with birth dose of HB
Number of subjects: 0
Study 30513252 — intervention group
Group type: COMPARATOR
Intervention: DTaP‐IPV‐HB‐PRPT primary and booster vaccination without birth dose of HB
Number of subjects: 0
Study 30513252 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP‐HB‐IPV//PRPT primary and booster vaccination
Number of subjects: 0
Study 30513252 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP‐IPV‐HB‐PRPT or DTaP‐HB‐IPV//PRPT booster
Number of subjects: 0
Study 28395375 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-week rehabilitation program
Number of subjects: 42
Study 25720600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Insulin Infusion (IV-I)
Number of subjects: 45
Study 25720600 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Insulin (SC-I)
Number of subjects: 45
Study 24393424 — intervention group
Group type: EXPERIMENTAL
Intervention: Presepsin (sCD14‐ST) measured on day 1
Number of subjects: 100
Study 24393424 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) measured on day 1
Number of subjects: 100
Study 24393424 — intervention group
Group type: EXPERIMENTAL
Intervention: Presepsin levels over time
Number of subjects: 100
Study 24393424 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin levels over time
Number of subjects: 100
Study 24393424 — intervention group
Group type: EXPERIMENTAL
Intervention: Presepsin as a predictor of mortality
Number of subjects: 100
Study 24393424 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic accuracy of Presepsin vs PCT
Number of subjects: 100
Study 21609254 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% alendronate gel
Number of subjects: 17
Study 21609254 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 17
Study 19546271 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered air-purifying respirators
Number of subjects: 14
Study 19546271 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional respirators
Number of subjects: 14
Study 19546271 — intervention group
Group type: COMPARATOR
Intervention: Control (unprotected)
Number of subjects: 14
Study 17309967 — intervention group
Group type: EXPERIMENTAL
Intervention: Italian Cleveland Global Quality of Life (CGQL) instrument
Number of subjects: 40
Study 17309967 — intervention group
Group type: EXPERIMENTAL
Intervention: Padova Inflammatory Bowel Disease Quality of Life instrument
Number of subjects: 40
Study 17310813 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddl)
Number of subjects: 168
Study 17310813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 14597353 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fraction of 8 Gy
Number of subjects: 102
Study 14597353 — intervention group
Group type: COMPARATOR
Intervention: Six fractions of 4 Gy
Number of subjects: 102
Study 14597353 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial cortical involvement >30 mm
Number of subjects: 102
Study 14597353 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial cortical involvement < or =30 mm
Number of subjects: 102
Study 14597353 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total dose irradiation or prophylactic surgery
Number of subjects: 102
Study 10650537 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-building intervention
Number of subjects: 0
Study 10650537 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 10650537 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 0
Study 10650537 — intervention group
Group type: COMPARATOR
Intervention: Cohesion measures (Individual attractions to the group‐social, Group integration‐social, Group integration‐task)
Number of subjects: 0
Study 8966062 — intervention group
Group type: EXPERIMENTAL
Intervention: During attack (I)
Number of subjects: 25
Study 8966062 — intervention group
Group type: EXPERIMENTAL
Intervention: After regression of symptoms (II)
Number of subjects: 25
Study 8966062 — intervention group
Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 25
Study 1802656 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP) given at a dose of 10 ml/kg daily for the first three days of life
Number of subjects: 38
Study 1802656 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 38
Study 1802656 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 38
Study 6363680 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural techniques to reduce swallowing rate
Number of subjects: 12
Study 30814777 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week home-based exercise program before TKA surgery
Number of subjects: 20
Study 30814777 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prehabilitation)
Number of subjects: 20
Study 28143564 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered within 3 hours of injury
Number of subjects: 20211
Study 28143564 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered after 3 hours of injury
Number of subjects: 20211
Study 28143564 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analyses for early TXA treatment
Number of subjects: 20211
Study 28143564 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analyses for late TXA treatment
Number of subjects: 20211
Study 28143564 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analysis of TXA effect
Number of subjects: 20211
Study 26060823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine-QR
Number of subjects: 1834
Study 26060823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1834
Study 23022602 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein yogurt snack (24 g protein)
Number of subjects: 15
Study 23022602 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate protein yogurt snack (14 g protein)
Number of subjects: 15
Study 23022602 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein yogurt snack (5 g protein)
Number of subjects: 15
Study 23022602 — intervention group
Group type: COMPARATOR
Intervention: No snack (NS)
Number of subjects: 15
Study 20671652 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose atorvastatin, titrated to maintain LDL cholesterol <100 mg/dL
Number of subjects: 100
Study 20671652 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (control group)
Number of subjects: 100
Study 20671652 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose atorvastatin
Number of subjects: 100
Study 17989103 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) at 2 g/day for 6 months along with prednisolone at 0.5 mg/kg/day for 2-3 months
Number of subjects: 54
Study 17989103 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy: prednisolone 1 mg/kg/day for 3-6 months for FSGS and alternating monthly cycles of steroids and cyclophosphamide for 6 months for MN
Number of subjects: 54
Study 17989103 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 54
Study 17989103 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 54
Study 15694878 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.08 mg/kg)
Number of subjects: 100
Study 15694878 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study 12886119 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural environment intervention (120 minutes of exposure per week)
Number of subjects: 157
Study 12886119 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention group (control)
Number of subjects: 157
Study 10540048 — intervention group
Group type: COMPARATOR
Intervention: Alpha2b‐interferon alone (3‐8 MU, three times weekly for 6 months)
Number of subjects: 50
Study 10540048 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Alpha2b‐interferon + ketoprofen 200 mg/day five times weekly)
Number of subjects: 50
Study 10540048 — intervention group
Group type: COMPARATOR
Intervention: Alpha2b‐interferon alone
Number of subjects: 50
Study 10540048 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 50
Study 8551786 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat (2 mg/kg per hour) during cardiopulmonary bypass
Number of subjects: 20
Study 8551786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nafamostat)
Number of subjects: 20
Study 1678039 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Number of subjects: 876
Study 1678039 — intervention group
Group type: COMPARATOR
Intervention: Chest physiotherapy
Number of subjects: 876
Study 6410730 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 46
Study 6410730 — intervention group
Group type: COMPARATOR
Intervention: Metrizamide
Number of subjects: 46
Study 31615771 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Number of subjects: 690
Study 31615771 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin 6
Number of subjects: 690
Study 31615771 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 690
Study 31615771 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided group
Number of subjects: 690
Study 31615771 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 690
Study 28202032 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-based health coaching intervention (monthly individual health coaching by telephone for 12 months)
Number of subjects: 1570
Study 28202032 — intervention group
Group type: COMPARATOR
Intervention: Routine social and health care (control group)
Number of subjects: 1570
Study 23489282 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2g daily for three months)
Number of subjects: 40
Study 23489282 — intervention group
Group type: COMPARATOR
Intervention: No metformin (control group)
Number of subjects: 40
Study 24206588 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (AS) monotherapy
Number of subjects: 143
Study 20581719 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (educational program + breathing exercises + aerobic training)
Number of subjects: 68
Study 20581719 — intervention group
Group type: COMPARATOR
Intervention: Control group (educational program + breathing exercises)
Number of subjects: 68
Study 19161878 — intervention group
Group type: EXPERIMENTAL
Intervention: EM-PCI (Export Medtronic thrombectomy device)
Number of subjects: 175
Study 17191233 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation-maximization (EM) algorithm with mixture of multivariate Gaussians (MoMG) for analyzing brain perfusion from DSC MR images
Number of subjects: 1
Study 17191233 — intervention group
Group type: COMPARATOR
Intervention: Results from normal subjects
Number of subjects: 1
Study 17191233 — intervention group
Group type: EXPERIMENTAL
Intervention: Results from a patient with CAVM
Number of subjects: 1
Study 15609766 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg
Number of subjects: 42
Study 15609766 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 10 mg
Number of subjects: 42
Study 10696827 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 2800
Study 10696827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 2800
Study 10696827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2800
Study 9350366 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (0.017 mg.kg‐1) with sevoflurane
Number of subjects: 30
Study 9350366 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (0.017 mg.kg‐1) with isoflurane
Number of subjects: 30
Study 9350366 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (0.017 mg.kg‐1) with enflurane
Number of subjects: 30
Study 1486156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 20
Study 1486156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg q.d.s.
Number of subjects: 20
Study 1486156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 600 mg b.d.
Number of subjects: 20
Study 1486156 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 20
Study 4040699 — intervention group
Group type: EXPERIMENTAL
Intervention: Functioning Uristop device
Number of subjects: 53
Study 4040699 — intervention group
Group type: COMPARATOR
Intervention: Non-functioning device (Control)
Number of subjects: 53
Study 4040699 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Functioning and Non-functioning devices)
Number of subjects: 53
Study 31779697 — intervention group
Group type: EXPERIMENTAL
Intervention: PG102P 1.5 g/day
Number of subjects: 80
Study 31779697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27192352 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity shave margins (CSM), n = 119
Number of subjects: 235
Study 27192352 — intervention group
Group type: COMPARATOR
Intervention: Standard partial mastectomy (no shave), n = 116
Number of subjects: 235
Study 27192352 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity shave margins (CSM)
Number of subjects: 235
Study 27192352 — intervention group
Group type: COMPARATOR
Intervention: Standard partial mastectomy (no shave)
Number of subjects: 235
Study 26407852 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vaginal progesterone until the 37th week of gestation or delivery
Number of subjects: 254
Study 26407852 — intervention group
Group type: COMPARATOR
Intervention: Cervical pessary until the 37th week of gestation or delivery
Number of subjects: 254
Study 23435698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfer intervention conditional on school attendance
Number of subjects: 29
Study 23435698 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 29
Study 21362524 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (0.01 μg kg(‐1) min(‐1) ± bolus)
Number of subjects: 89
Study 21362524 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (maximally tolerated doses by standard protocol)
Number of subjects: 89
Study 21362524 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide and Nitroglycerin
Number of subjects: 89
Study 19625139 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant breast radiotherapy (RT)
Number of subjects: 0
Study 19625139 — intervention group
Group type: COMPARATOR
Intervention: Non-radiotherapy (non-RT)
Number of subjects: 0
Study 17179242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative cerebral regional oxygen saturation (rSO2) monitoring with active display and treatment intervention protocol (n = 100)
Number of subjects: 200
Study 17179242 — intervention group
Group type: COMPARATOR
Intervention: Blinded rSO2 monitoring (n = 100)
Number of subjects: 200
Study 15369567 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient chemical dependency treatment
Number of subjects: 925
Study 14622826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive/emotional stress (20-minute Stroop test)
Number of subjects: 0